DK1470102T3 - Substituerede methylenamidderivater som modulatorer af proteintyrosinphosphataser (PTPS) - Google Patents

Substituerede methylenamidderivater som modulatorer af proteintyrosinphosphataser (PTPS)

Info

Publication number: DK1470102T3
Authority: DK; Denmark
Prior art keywords: present; ptps; derivatives; formula; substituted
Prior art date: 2002-01-29

Application number

DK03734697.0T

Other languages

English (en)

Inventor

Agnes Bombrun

Pierre-Andre Pittet

Patrick Gerber

Dominique Swinnen

Jera Me Gonzalez

Original Assignee

Merck Serono Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-01-29

Filing date

2003-01-27

Publication date

2011-06-20

2003-01-27 Application filed by Merck Serono Sa filed Critical Merck Serono Sa

2011-06-20 Application granted granted Critical

2011-06-20 Publication of DK1470102T3 publication Critical patent/DK1470102T3/da

Links

WDWDWGRYHDPSDS-UHFFFAOYSA-N methanimine Chemical class N=C WDWDWGRYHDPSDS-UHFFFAOYSA-N 0.000 title abstract 4
102000002727 Protein Tyrosine Phosphatase Human genes 0.000 title 2
108020000494 protein-tyrosine phosphatase Proteins 0.000 title 2
206010022489 Insulin Resistance Diseases 0.000 abstract 2
208000008589 Obesity Diseases 0.000 abstract 2
206010012601 diabetes mellitus Diseases 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
235000020824 obesity Nutrition 0.000 abstract 2
201000010065 polycystic ovary syndrome Diseases 0.000 abstract 2
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
230000036528 appetite Effects 0.000 abstract 1
235000019789 appetite Nutrition 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
239000008103 glucose Substances 0.000 abstract 1
208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
208000030159 metabolic disease Diseases 0.000 abstract 1
229920001469 poly(aryloxy)thionylphosphazene Polymers 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/56—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having carbon atoms of carboxamide groups bound to carbon atoms of carboxyl groups, e.g. oxamides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Pregnancy & Childbirth (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Epidemiology (AREA)
Gynecology & Obstetrics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Thiazole And Isothizaole Compounds (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Pyridine Compounds (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Furan Compounds (AREA)
Hydrogenated Pyridines (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Plural Heterocyclic Compounds (AREA)

DK03734697.0T 2002-01-29 2003-01-27 Substituerede methylenamidderivater som modulatorer af proteintyrosinphosphataser (PTPS) DK1470102T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP02100078		2002-01-29
EP02100410		2002-04-25
PCT/EP2003/000808 WO2003064376A1 (en)	2002-01-29	2003-01-27	Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases (ptps)

Publications (1)

Publication Number	Publication Date
DK1470102T3 true DK1470102T3 (da)	2011-06-20

Family

ID=27664997

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK03734697.0T DK1470102T3 (da)	2002-01-29	2003-01-27	Substituerede methylenamidderivater som modulatorer af proteintyrosinphosphataser (PTPS)

Country Status (23)

Country	Link
US (1)	US7592477B2 (da)
EP (1)	EP1470102B1 (da)
JP (2)	JP4828793B2 (da)
KR (1)	KR100922041B1 (da)
CN (1)	CN100410236C (da)
AT (1)	ATE510817T1 (da)
AU (1)	AU2003239296B2 (da)
BR (1)	BR0307394A (da)
CA (1)	CA2472021C (da)
CY (1)	CY1111576T1 (da)
DK (1)	DK1470102T3 (da)
EA (1)	EA012260B1 (da)
HR (1)	HRP20040612A2 (da)
IL (1)	IL163144A (da)
MX (1)	MXPA04007253A (da)
NO (1)	NO329742B1 (da)
PL (1)	PL207295B1 (da)
PT (1)	PT1470102E (da)
RS (1)	RS51865B (da)
SI (1)	SI1470102T1 (da)
UA (1)	UA82661C2 (da)
WO (1)	WO2003064376A1 (da)
ZA (1)	ZA200405179B (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1654247B1 (en)	2003-07-21	2010-01-20	Merck Serono SA	Alkynyl aryl carboxamides
SI1656139T1 (sl) *	2003-07-21	2011-12-30	Merck Serono Sa	Aril dikarboksamidi
DK1675813T3 (da)	2003-10-13	2008-03-03	Serono Lab	Fremgangsmåde til fremstilling af para-phenylalkynylbenzaldehyder
CA2554919C (en) *	2004-02-27	2013-04-16	Applied Research Systems Ars Holding N.V.	Use of methylene amide derivatives in cardiovascular disorders
BRPI0508790A (pt) *	2004-04-07	2007-09-04	Applied Research Systems	ácido carboxìlicos, uso de um ácido carboxìlico, composto farmacêutico, método de preparação de ácido carboxìlico e composto intermediário
CN1942428A (zh) *	2004-04-13	2007-04-04	默克公司	Cetp抑制剂
US7517991B2 (en) *	2004-10-12	2009-04-14	Bristol-Myers Squibb Company	N-sulfonylpiperidine cannabinoid receptor 1 antagonists
PT1904048E (pt) *	2005-07-15	2011-12-19	Merck Serono Sa	Inibidores de glepp-1 no tratamento de distúrbios autoimunes e/ou inflamatórios
WO2007028145A2 (en) *	2005-09-02	2007-03-08	Dara Biosciences, Inc.	Agents and methods for reducing protein tyrosine phosphatase 1b activity in the central nervous system
US7888376B2 (en)	2005-11-23	2011-02-15	Bristol-Myers Squibb Company	Heterocyclic CETP inhibitors
JP5773560B2 (ja)	2006-02-09	2015-09-02	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	Ｃｅｔｐ阻害剤のポリマー製剤
EP1986637A1 (en) *	2006-02-13	2008-11-05	Laboratoires Serono SA	Sulfonamide derivatives for the treatment of bacterial infections
EP2072498A4 (en)	2006-10-12	2012-07-18	Inst Med Molecular Design Inc	N-PHENYLOXAMIDINSÄUREDERIVAT
US8633245B2 (en) *	2008-04-11	2014-01-21	Institute Of Medicinal Molecular Design, Inc.	PAI-1 inhibitor
KR20120104087A (ko) *	2010-08-05	2012-09-20	이데미쓰 고산 가부시키가이샤	유기 전계 발광 소자
CN102512407B (zh) *	2011-11-23	2014-05-21	中山大学	一种β-苯丙氨酸类化合物作为醛糖还原酶抑制剂的应用
MX2015005739A (es) *	2012-11-06	2015-09-16	Lilly Co Eli	Compuestos novedosos de bencil sulfonamida utiles como inhibidores de mogat-2.
CA2921427A1 (en) *	2013-08-16	2015-02-19	Duke University	Substituted hydroxamic acid compounds
WO2020104635A1 (en) *	2018-11-23	2020-05-28	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of shp2 inhibitors for the treatment of insulin resistance
EP4132523A4 (en) *	2020-04-06	2024-05-15	Purdue Research Foundation	Novel n-aryl oxamic acids
CN114478522B (zh) *	2022-01-25	2023-07-28	山东大学	一种吡啶并咪唑类衍生物及其制备方法与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5217482A (en) *	1975-07-25	1977-02-09	Sumitomo Chem Co Ltd	Preparation of quinazolinone derivatives
CA2054339C (en) *	1990-11-02	2002-12-24	Francesco G. Salituro	3-amidoindolyl derivatives
DE69529770T2 (de)	1994-12-02	2003-12-24	Yamanouchi Pharmaceutical Co., Ltd.	Neues amidinonaphthylderivat oder dessen salz
JPH08295667A (ja) *	1995-04-27	1996-11-12	Takeda Chem Ind Ltd	複素環化合物、その製造法および剤
JP3283485B2 (ja) *	1998-04-10	2002-05-20	日本たばこ産業株式会社	アミジン化合物
US6488973B1 (en) *	1998-10-05	2002-12-03	Food Talk, Inc.	Method of making a cooking pouch containing a raw protein portion, a raw or blanched vegetable portion and a sauce
EP1123928A4 (en)	1998-10-20	2005-02-16	Takeda Pharmaceutical	1,5-BENZODIAZEPINE COMPOUNDS, PROCESS FOR PRODUCING THE SAME, AND MEDICAMENT
JP2003509429A (ja) *	1999-09-10	2003-03-11	ノボノルディスクアクティーゼルスカブ	タンパク質チロシンホスファターゼ（ｐｔｐアーゼ）のモジュレーター
US6627767B2 (en) *	2000-08-29	2003-09-30	Abbott Laboratories	Amino(oxo) acetic acid protein tyrosine phosphatase inhibitors
WO2002018321A2 (en)	2000-08-29	2002-03-07	Abbott Laboratories	Amino(oxo)acetic acid protein tyrosine phosphatase inhibitors
US20020198203A1 (en)	2001-06-07	2002-12-26	Wyeth	Combination of a PTPase inhibitor and a thiazolidinedione agent
CA2554919C (en) *	2004-02-27	2013-04-16	Applied Research Systems Ars Holding N.V.	Use of methylene amide derivatives in cardiovascular disorders

2003
- 2003-01-27 CN CNB038070367A patent/CN100410236C/zh not_active Expired - Fee Related
- 2003-01-27 AU AU2003239296A patent/AU2003239296B2/en not_active Ceased
- 2003-01-27 PT PT03734697T patent/PT1470102E/pt unknown
- 2003-01-27 HR HR20040612A patent/HRP20040612A2/xx not_active Application Discontinuation
- 2003-01-27 KR KR1020047011772A patent/KR100922041B1/ko not_active Expired - Fee Related
- 2003-01-27 US US10/501,344 patent/US7592477B2/en not_active Expired - Fee Related
- 2003-01-27 AT AT03734697T patent/ATE510817T1/de active
- 2003-01-27 CA CA2472021A patent/CA2472021C/en not_active Expired - Fee Related
- 2003-01-27 MX MXPA04007253A patent/MXPA04007253A/es active IP Right Grant
- 2003-01-27 UA UA20040706337A patent/UA82661C2/uk unknown
- 2003-01-27 JP JP2003564000A patent/JP4828793B2/ja not_active Expired - Fee Related
- 2003-01-27 PL PL371198A patent/PL207295B1/pl not_active IP Right Cessation
- 2003-01-27 BR BR0307394-7A patent/BR0307394A/pt not_active IP Right Cessation
- 2003-01-27 EP EP03734697A patent/EP1470102B1/en not_active Expired - Lifetime
- 2003-01-27 SI SI200332010T patent/SI1470102T1/sl unknown
- 2003-01-27 DK DK03734697.0T patent/DK1470102T3/da active
- 2003-01-27 RS YU65304A patent/RS51865B/sr unknown
- 2003-01-27 WO PCT/EP2003/000808 patent/WO2003064376A1/en not_active Ceased
- 2003-01-27 EA EA200400882A patent/EA012260B1/ru not_active IP Right Cessation
2004
- 2004-06-29 ZA ZA2004/05179A patent/ZA200405179B/en unknown
- 2004-07-22 IL IL163144A patent/IL163144A/en not_active IP Right Cessation
- 2004-08-24 NO NO20043520A patent/NO329742B1/no not_active IP Right Cessation
2011
- 2011-06-16 CY CY20111100576T patent/CY1111576T1/el unknown
- 2011-06-30 JP JP2011146082A patent/JP2011256174A/ja active Pending

Also Published As

Publication number	Publication date
CN100410236C (zh)	2008-08-13
HK1073649A1 (en)	2005-10-14
AU2003239296B2 (en)	2008-10-23
IL163144A (en)	2012-07-31
JP2011256174A (ja)	2011-12-22
MXPA04007253A (es)	2004-10-29
CA2472021A1 (en)	2003-08-07
JP4828793B2 (ja)	2011-11-30
EA200400882A1 (ru)	2005-04-28
CN1633410A (zh)	2005-06-29
SI1470102T1 (sl)	2011-08-31
RS65304A (sr)	2007-02-05
EA012260B1 (ru)	2009-08-28
US7592477B2 (en)	2009-09-22
EP1470102A1 (en)	2004-10-27
UA82661C2 (uk)	2008-05-12
ATE510817T1 (de)	2011-06-15
PT1470102E (pt)	2011-06-06
JP2005516061A (ja)	2005-06-02
NO20043520L (no)	2004-10-05
KR20040104953A (ko)	2004-12-13
NO329742B1 (no)	2010-12-13
EP1470102B1 (en)	2011-05-25
KR100922041B1 (ko)	2009-10-19
RS51865B (sr)	2012-02-29
PL371198A1 (en)	2005-06-13
CA2472021C (en)	2012-08-14
HRP20040612A2 (en)	2005-04-30
BR0307394A (pt)	2004-11-09
CY1111576T1 (el)	2015-10-07
WO2003064376A1 (en)	2003-08-07
ZA200405179B (en)	2005-08-31
US20050124656A1 (en)	2005-06-09
PL207295B1 (pl)	2010-11-30

Publication	Publication Date	Title
CY1111576T1 (el)	2015-10-07	Υποκατεστημενα παραγωγα μεθυλενο αμιδης ως ρυθμιστες των φωσφατασων πρωτεϊνης τυροσινης(ptps)
EA200601869A1 (ru)	2007-04-27	Карбоновые кислоты
EA200870476A1 (ru)	2009-04-28	Ингибиторы 11-бета-гидроксистероид дегидрогеназы 1
DK2029529T3 (da)	2010-09-20	Substitueret pyrrolidinone som inhibitor af 11-beta-hydroxysteroiddehydrogenase 1
EA200400011A1 (ru)	2004-06-24	Модуляторы рецепторов, активируемых пролифераторами пероксисом (prar)
EA200870489A1 (ru)	2009-04-28	Пиперидинилзамещённые пирролидиноны в качестве ингибиторов 11-бета-гидроксистероид дегидрогеназы 1
EA200870460A1 (ru)	2009-04-28	Производные циклогексилпиразол-лактама в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы 1
EA200870470A1 (ru)	2009-04-28	Ингибиторы 11-бета-гидроксистероид дегидрогеназы 1
BR0313266A (pt)	2005-06-21	Compostos, respectivos processos de preparação e uso, formulação farmacêutica e métodos de prevenção e/ou tratamento de um distúrbio mediado pelo receptor de mglur5 e de inibição da ativação de receptores de mglur5
CY1114660T1 (el)	2016-10-05	ΠΑΡΑΓΩΓΑ 2-ΑΔΑΜΑΝΤΥΛΟΥΡΙΑΣ ΩΣ ΕΚΛΕΚΤΙΚΟΙ ΑΝΑΣΤΟΛΕΙΣ 11β-HSD1
DK2035379T3 (da)	2010-09-06	Inhibitorer af 11-beta-hydroxysteroiddehydrogenase 1
BRPI0507481A (pt)	2007-07-17	composto, composição farmacêutica, uso do composto, e, métodos para tratar distúrbios mediados por mglur 5 e para inibir ativação de receptores de mglur 5
EA200600240A1 (ru)	2006-08-25	Конденсированные арильные и гетероарильные производные в качестве модуляторов метаболизма и для профилактики и лечения расстройств, связанных с нарушением матеболизма
BR0210383A (pt)	2006-04-04	compostos para o tratamento de distúrbios metabólicos
CY1112398T1 (el)	2015-12-09	Πυρρολιδινονες υποκατασταθεισες απο κυκλοεξυλιο ως αναστολεις της 11-β-υδροξυστεροειδικης αφυδρογονασης 1
TW200602324A (en)	2006-01-16	Tetrahydro-indazole cannabinoid modulators cross reference to related applications
EA200400980A1 (ru)	2005-02-24	Ингибиторы асс
UA84390C2 (ru)	2008-10-27	Производные амидов как активаторы глюкокиназы
EA201300550A1 (ru)	2014-02-28	Фармацевтическая композиция, способы лечения и их применение
EA200970398A1 (ru)	2009-08-28	Производные пиперидин или пиперазин замещенной тетрагидро-нафталин 1-карбоновой кислоты, ингибирующие мтр
EA200800888A1 (ru)	2009-02-27	Модуляторы каннабиноидов на основе замещенных 3-амидотетрагидроиндазолилов
BRPI0417469B8 (pt)	2021-05-25	bifenil carboxamidas substituídas com n-aril piperidina, composição farmacêutica que os compreende e processo de preparação destes
BRPI0717314A2 (pt)	2014-01-21	Derivados de ácido tetra-hidro-naftaleno-1-carboxílico inibidores de mtp
BRPI0510451A (pt)	2007-10-30	compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas de ppar(delta) e/ou de ppar(alfa) e sua utilização
ATE534387T1 (de)	2011-12-15	Hexahydro-cycloheptapyrazol-cannabinoid- modulatoren